Jlb & Associates Inc sold 4,991 shares as Colgate Palmolive (CL)'s stock 0.00%.
On last trading day, Carrizo Oil & Gas, Inc. Insiders have sold a total of 39,833 shares of company stock valued at $2,894,929 in the last quarter.
Colgate-Palmolive Company (NYSE:CL) shares moved to $75.69 after opening the day at $73.93, on Wednesday. It has by 0.00% the S&P500. Piedmont Invest Advisors Ltd Llc reported 182,741 shares. The stock notched a 12-month high of $75.45 while $90.00 target is by far the most aggressive out of analysts who are now evaluating the company, $14.55 higher than the next highest 52-week price estimate. CVV's SI was 334,700 shares in May as released by FINRA. Apple Inc Com now has $795.32B valuation. Traders acquired 24,552 call options on the stock. About 12,584 shares traded. Biotech Products Services & Research Inc (OTCMKTS:BPSR) has risen 6.00% since April 19, 2017 and is uptrending. $270,546 worth of stock was sold by THOMPSON DELIA H on Tuesday, February 21.
15 number of analysts have estimated the sales of the company for the quarter ending Jul 21, 2017, analysts estimated mean sale target of 3951.34 million while high and low sale targets are estimated at 4010 million and 3845 million respectively.
In other news, insider Patricia Verduin sold 3,833 shares of the stock in a transaction that occurred on Monday, April 17th. 2,418 shares were sold by Deoras Mukul, worth $176,901. Another trade for 7,293 shares valued at $533,556 was sold by Marsili Daniel B.
Colgate-Palmolive Company (NYSE:CL) last posted its quarterly earnings results on Friday, April 28th. CL's profit will be $672.47M for 25.67 P/E if the $0.72 EPS becomes a reality. The company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.01. Fourteen equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Therefore 14% are positive. The firm has "Overweight" rating given on Wednesday, January 6 by Atlantic Securities. The company was maintained on Friday, October 28 by UBS. Mean recommendation on this stock is 2.20. The ex-dividend date was Wednesday, April 19th. The stock has "Equal-Weight" rating by Barclays Capital on Monday, March 21.
Beta is also an important valuation ratio for analyzing the stock of the company, CL has Beta of 0.82 while its industry and Sector's beta remains at 0.64 and 0.67 respectively. Stifel Nicolaus maintained it with "Hold" rating and $70 target in Monday, January 30 report.
The stock decreased 10.00% or $0.001 on May 18, reaching $0.009. Its down 0.75, from 2.75 in 2016Q3. It is negative, as 53 investors sold CL shares while 472 reduced holdings. 91 funds opened positions while 363 raised stakes. Deutsche Fincl Bank Ag holds 0% or 3,268 shares. Colgate-Palmolive Company had a return on equity of 4,897.09% and a net margin of 16.06%. Fjarde Ap reported 155,720 shares.
Colgate-Palmolive Company (CL) now has P/E (Price to Earnings) ratio of 25.89 while the company's industry has 72.42 P/E and the sector P/E is 41.26. Quadrant Capital Group LLC boosted its position in Colgate-Palmolive Company by 200.6% in the third quarter. Reliant Management Lc holds 9,280 shares or 0.49% of its portfolio. 8,596 were accumulated by Sigma Planning. BNP Paribas upgraded Colgate-Palmolive Company from a "neutral" rating to an "outperform" rating in a research note on Tuesday, February 21st. Janney Montgomery Scott Llc has 72,730 shares for 0.01% of their portfolio. 63,025 are held by Coastline Tru. Ipswich Mgmt Comm, Massachusetts-based fund reported 43,007 shares.
Investors sentiment decreased to 0.79 in 2016 Q4. The California-based National Planning Corp has invested 0.25% in the stock.
Corporation (NYSE:ORCL)'s shares are trading at $44.46 with incline of 0.66%. Gyroscope Group Incorporated Limited accumulated 0.16% or 3,600 shares. About 1.65M shares traded. Cap Advisers Lc has 1.64 million shares for 1.85% of their portfolio.
What Analysts Say About Kite Pharma, Inc. (CL) is $75.33/share according to the consensus of analysts working on the stock, with an expected EPS of $0.72/share for the current quarter. Nonetheless, from here on out, earnings per share forecasts for the current quarter are $0.72.
Ratings analysis reveals 80% of LeMaitre Vascular's analysts are positive. The Return on Invested Capital is a ratio that determines whether a company is profitable or not. The firm has "Market Perform" rating given on Monday, October 26 by Cowen & Co.